Kanner Steven 4
4 · Caribou Biosciences, Inc. · Filed Mar 7, 2022
Insider Transaction Report
Form 4
Kanner Steven
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2022-03-04$2.69/sh+9,171$24,670→ 226,090 total - Exercise/Conversion
Common Stock
2022-03-04$4.11/sh+1,549$6,366→ 227,639 total - Exercise/Conversion
Option to purchase Common Stock
2022-03-04−9,171→ 122,963 totalExercise: $2.69Exp: 2029-09-30→ Common Stock (9,171 underlying) - Exercise/Conversion
Option to purchase Common Stock
2022-03-04−1,549→ 230,365 totalExercise: $4.11Exp: 2031-03-29→ Common Stock (1,549 underlying)
Footnotes (4)
- [F1]Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.68 per share on the reporting person's Form 3 filed on July 22, 2021.
- [F2]Includes 1,888 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2022 for $9.85 per share.
- [F3]1/4th of the shares subject to this option vested on October 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
- [F4]1/4th of the shares subject to this option vested on March 2, 2022 and an additional 1/48th of the aggregate number of shares subject to the option will vest on the corresponding day of each month thereafter until the option is fully vested, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.